Introduction
Nitrosamine risk in a finished drug product can originate from an excipient that never touches the active ingredient directly. This is the part of nitrosamine risk assessment that catches formulation teams off guard. The conversation around nitrosamines has mostly focused on active pharmaceutical ingredients and their synthesis routes, yet pharmaceutical coating polymers and other excipients carry their own nitrite load and that load is rarely zero.
The consequence of overlooking this is not abstract. A drug product can pass every test on the API side and still accumulate nitrosamine impurities over shelf life if the excipients in the formulation bring nitrite content into contact with amines from the API or from other excipients. Regulators have made this connection explicit. The FDA's revised guidance on controlling nitrosamine impurities extends risk assessment expectations across the full formulation and not just the synthesis route, and it includes a dedicated treatment of nitrosamine drug substance related impurities that earlier guidance did not cover.
For GMP excipient manufacturers, this changes what a quality conversation with a customer looks like. A formulator evaluating a coating polymer or a diluent for a regulated market now needs nitrite level data, batch consistency evidence and a documented risk position from the supplier before the excipient is even sampled. At Vikram Thermo (India) Ltd., we have built our quality systems around EXCiPACT GMP certification and US DMF registration with this expectation in mind. This article sets out what that documentation should contain and how a formulation team should use it.
What Is Nitrosamine Risk in Excipients
Nitrosamines are a class of N-nitroso compounds that form when a nitrosating agent reacts with a secondary or tertiary amine. In a drug product, the amine can come from the active ingredient, from another excipient or from a degradation product. The nitrosating agent is most often a nitrite, and nitrites are not exotic contaminants. They occur at low levels in many widely used excipients, including diluents, binders and coating materials, as residual material from raw material sourcing or from the manufacturing process itself.
The risk is not that an excipient contains nitrosamines. In most cases it does not. The risk is that the excipient contributes nitrite, and nitrite combined with an amine under the right conditions of pH, temperature and storage time can form a nitrosamine over the life of the product. This is why nitrosamine risk assessment is described as a formulation level exercise rather than a single material test. Every excipient in the formulation is a potential contributor, and the contribution depends on both the nitrite level in that excipient and how the formulation behaves over its shelf life.
For a coating polymer, including a gastro-resistant coating polymer used in enteric systems, the relevant question is not only what is in the polymer as supplied. It is also how the polymer behaves during processing and storage, since nitrosamine formation can in some cases occur during the coating process itself if conditions allow it.
Why It Matters
A nitrosamine finding after a product is already on the market is one of the most disruptive events a manufacturer can face. Since 2018, regulators have recalled more than 1,200 drug product lots globally after detecting nitrosamine impurities. The most visible example remains 2020, when the FDA requested the full market withdrawal of ranitidine products in the United States after NDMA levels in some products exceeded the acceptable intake limit of 96 nanograms per day. These recalls were not limited to one drug class or one manufacturer. They affected multiple therapeutic categories and multiple supply chains at once.
For a formulator, the practical impact of this history is that nitrosamine risk assessment is no longer documentation kept in a drawer. Inspection trends increasingly reveal gaps in nitrosamine risk assessment and impurity control, which means the assessment has become a standing item that inspectors look for and not a one-time exercise completed at initial registration.
This is where excipient selection becomes a compliance decision and not only a performance decision. A coating polymer that performs identically to another on dissolution and appearance can still carry a different nitrite profile. That difference becomes the formulator's problem the moment a nitrosamine is detected in stability testing, often years after the formulation was finalised.
How Nitrosamine Formation Happens in a Formulation
Three conditions need to be present together for a nitrosamine to form: a nitrosating agent, an amine and an environment that allows the reaction to proceed. Remove any one of these and the risk drops sharply.
The nitrosating agent. Nitrite is the most common source. It can be present as a trace impurity in excipients such as diluents, fillers and certain coating polymers, usually originating from the raw materials or water used in their manufacture rather than from the finished excipient's intended chemistry.
The amine. This can come from the API itself, particularly APIs with secondary or tertiary amine groups, or from amine containing excipients and additives used elsewhere in the formulation.
The environment. Acidic conditions accelerate nitrosation. So does elevated temperature and extended storage time. A formulation stored at room temperature for two years has more opportunity for a slow reaction to proceed than one with a shorter shelf life, which is why nitrosamine risk assessments must account for the full labelled shelf life and not just initial release testing.
A formulator who understands which of these three elements is present in their formulation can target the assessment instead of testing everything against everything. If the API has no amine functionality and no amine containing excipients are used, the nitrite content of individual excipients becomes far less critical. If the API does carry an amine group, nitrite contributing excipients deserve close attention regardless of how small the contribution looks on paper.
What a Risk Assessment Actually Requires
The FDA's three step framework gives structure to what would otherwise be an open ended exercise. The first step is a paper based risk assessment covering the API synthesis route, the excipients in the formulation and the packaging materials. The second step is confirmatory testing where risk is identified, generally following established analytical methods such as USP General Chapter 1469. The third step is implementing process or formulation changes where testing confirms a risk above acceptable limits.
Acceptable intake limits are expressed in nanograms per day and vary by nitrosamine. NDMA and NMBA carry an acceptable intake limit of 96 nanograms per day, while NDEA, NMPA, NIPEA and NDIPA carry a limit of 26.5 nanograms per day. These limits are converted into a parts per million specification based on the drug product's maximum daily dose, which means the same excipient nitrite level can represent a different level of risk depending on the dosage form it ends up in.
For nitrosamine drug substance related impurities, which are structurally similar to the API itself, the FDA has introduced a Carcinogenic Potency Categorization Approach that assigns compounds into five potency categories with acceptable intake limits ranging from 26.5 to 1500 nanograms per day. This matters for formulators working with APIs that have complex amine structures, where a generic excipient nitrite specification is not sufficient on its own.
What Suppliers Should Provide
This is the section that determines whether a formulator can complete a risk assessment without chasing information from multiple sources.
Nitrite content data on the excipient itself. A documented nitrite level, ideally with batch to batch consistency data over time rather than a single historical measurement. Diluents used in larger proportions in a formulation typically show nitrite levels around 1 microgram per gram with low variability, and a supplier who can demonstrate this consistency removes one variable from the formulator's assessment entirely.
A written position on nitrosamine risk for the excipient. This does not need to be a full risk assessment of the customer's formulation, which is not the supplier's responsibility. It needs to state clearly what the excipient contributes, under what conditions, and what data supports that statement.
Manufacturing process information relevant to nitrosamine formation. Where in the process nitrite could be introduced, and what controls are in place to limit it. This is not a request for proprietary process detail. It is a request for the formulator to understand whether the nitrite level they see today is representative of what they will see across future batches.
Change notification commitments. If a raw material source, a process step or a specification changes in a way that could affect nitrite content, the formulator needs to know before the change happens, not after a stability failure prompts an investigation.
Certifications that support the documentation. EXCiPACT GMP certification and US DMF registration are not nitrosamine specific certifications, but they establish the quality system context within which nitrite data is generated and maintained. A supplier operating under these frameworks has the traceability infrastructure to answer follow up questions, which matters when an assessment needs to be revisited after a regulatory update.
This is the standard a formulator should expect from any pharma raw material supplier in India working in regulated markets. Whether the requirement is for a tablet coating materials supplier or a broader pharmaceutical ingredients supplier across the formulation, the documentation expectation does not change. Excipient supplier qualification for a regulated market formulation should treat this nitrite and risk documentation as a standard part of the technical package, not an exception requested only when a query arises.
Applications by Dosage Form
Common Challenges
Treating excipient nitrite as a fixed specification rather than a range. Nitrite levels can vary between batches even within a supplier's stated specification. A formulator who builds a risk assessment around a single historical value rather than a range may find the assessment no longer holds when a new batch arrives.
Assuming a low individual contribution means no formulation level risk. Multiple excipients each contributing a small amount of nitrite can combine to a level that matters, particularly in formulations with several diluents, binders and coating materials.
Incomplete documentation chains during supplier qualification. When nitrite data exists but is not readily available in a format that supports a regulatory submission, the formulator ends up requesting it reactively, often under time pressure during an audit or a query response.
Reassessing only at the time of a regulatory update. Nitrosamine guidance has changed multiple times since 2020. A risk assessment completed against an earlier version of the guidance may not address newer categories such as nitrosamine drug substance related impurities, and formulations approved before these categories existed may need a fresh look.
Formulation Insights
The relationship between excipient selection and nitrosamine risk is not a reason to avoid any particular excipient category. It is a reason to ask for the right data at the right point in the selection process. A tablet coating polymer manufacturer that documents nitrite consistency and provides a clear process narrative gives a formulation team a head start on their risk assessment that cannot be recovered later if the same questions are raised only after the formulation is locked.
Where a formulation includes an API with known amine functionality, the nitrite contribution from the coating system deserves the same attention as the nitrite contribution from the core tablet excipients. Coating represents the outermost layer of the dosage form and the layer in closest contact with the storage environment over the product's shelf life.
FAQ
1. Does every excipient need a nitrosamine risk assessment?
Every excipient should be considered as part of the formulation level assessment, but the depth of assessment depends on whether the API carries amine functionality and whether the excipient is a known nitrite contributor. Diluents used in large proportions and any amine containing excipients warrant the closest attention.
2. Can a low nitrite level in an excipient still cause a problem?
Yes, if multiple excipients in the formulation each contribute a small amount of nitrite and the API carries an amine group, the combined effect over the shelf life can exceed acceptable limits even when no single excipient looks concerning on its own.
3. How often should nitrite data be requested from a supplier?
At initial qualification and again whenever a regulatory update introduces new impurity categories or revised acceptable intake limits. A supplier with stable, documented batch to batch consistency reduces the need for frequent re-testing.
4. Is EXCiPACT GMP certification a nitrosamine specific certification?
No. It certifies the quality management system under which the excipient is produced, which supports the traceability and documentation needed to respond to nitrosamine related queries, but it does not itself certify nitrite levels.
5. What is the difference between a nitrosamine and a nitrosamine drug substance related impurity?
A nitrosamine drug substance related impurity, or NDSRI, is structurally similar to the API itself rather than being one of the well characterised nitrosamines like NDMA or NDEA. NDSRIs are assessed using the Carcinogenic Potency Categorization Approach, which assigns acceptable intake limits based on structural similarity to known carcinogens.
Conclusion
The formulations most exposed to nitrosamine risk are not the ones with the most complex chemistry. They are the ones where the risk assessment was completed once, against an earlier set of expectations, and never revisited as guidance expanded to cover new impurity categories and new sources. An excipient supplier who can provide nitrite data, batch consistency evidence and a documented manufacturing narrative turns a formulation level risk assessment from a research exercise into a documentation review.
We are India's first EXCiPACT GMP certified polymer excipient manufacturer, and as a pharmaceutical excipient manufacturer in India we are registered under the US DMF and operate under WHO cGMP compliance across the full range. Our quality documentation is structured to support the nitrite level and process information that a nitrosamine risk assessment requires.
Facing Nitrosamine Risk in Your Formulation? Talk to Us.
Tell us which excipients are in your formulation and what stage your risk assessment has reached. We will share the nitrite data and documentation relevant to our products and help you understand where they fit in your assessment.
Write to us at contact@vikramthermo.com
Introduction
Nitrosamine risk in a finished drug product can originate from an excipient that never touches the active ingredient directly. This is the part of nitrosamine risk assessment that catches formulation teams off guard. The conversation around nitrosamines has mostly focused on active pharmaceutical ingredients and their synthesis routes, yet pharmaceutical coating polymers and other excipients carry their own nitrite load and that load is rarely zero.
The consequence of overlooking this is not abstract. A drug product can pass every test on the API side and still accumulate nitrosamine impurities over shelf life if the excipients in the formulation bring nitrite content into contact with amines from the API or from other excipients. Regulators have made this connection explicit. The FDA's revised guidance on controlling nitrosamine impurities extends risk assessment expectations across the full formulation and not just the synthesis route, and it includes a dedicated treatment of nitrosamine drug substance related impurities that earlier guidance did not cover.
For GMP excipient manufacturers, this changes what a quality conversation with a customer looks like. A formulator evaluating a coating polymer or a diluent for a regulated market now needs nitrite level data, batch consistency evidence and a documented risk position from the supplier before the excipient is even sampled. At Vikram Thermo (India) Ltd., we have built our quality systems around EXCiPACT GMP certification and US DMF registration with this expectation in mind. This article sets out what that documentation should contain and how a formulation team should use it.
What Is Nitrosamine Risk in Excipients
Nitrosamines are a class of N-nitroso compounds that form when a nitrosating agent reacts with a secondary or tertiary amine. In a drug product, the amine can come from the active ingredient, from another excipient or from a degradation product. The nitrosating agent is most often a nitrite, and nitrites are not exotic contaminants. They occur at low levels in many widely used excipients, including diluents, binders and coating materials, as residual material from raw material sourcing or from the manufacturing process itself.
The risk is not that an excipient contains nitrosamines. In most cases it does not. The risk is that the excipient contributes nitrite, and nitrite combined with an amine under the right conditions of pH, temperature and storage time can form a nitrosamine over the life of the product. This is why nitrosamine risk assessment is described as a formulation level exercise rather than a single material test. Every excipient in the formulation is a potential contributor, and the contribution depends on both the nitrite level in that excipient and how the formulation behaves over its shelf life.
For a coating polymer, including a gastro-resistant coating polymer used in enteric systems, the relevant question is not only what is in the polymer as supplied. It is also how the polymer behaves during processing and storage, since nitrosamine formation can in some cases occur during the coating process itself if conditions allow it.
Why It Matters
A nitrosamine finding after a product is already on the market is one of the most disruptive events a manufacturer can face. Since 2018, regulators have recalled more than 1,200 drug product lots globally after detecting nitrosamine impurities. The most visible example remains 2020, when the FDA requested the full market withdrawal of ranitidine products in the United States after NDMA levels in some products exceeded the acceptable intake limit of 96 nanograms per day. These recalls were not limited to one drug class or one manufacturer. They affected multiple therapeutic categories and multiple supply chains at once.
For a formulator, the practical impact of this history is that nitrosamine risk assessment is no longer documentation kept in a drawer. Inspection trends increasingly reveal gaps in nitrosamine risk assessment and impurity control, which means the assessment has become a standing item that inspectors look for and not a one-time exercise completed at initial registration.
This is where excipient selection becomes a compliance decision and not only a performance decision. A coating polymer that performs identically to another on dissolution and appearance can still carry a different nitrite profile. That difference becomes the formulator's problem the moment a nitrosamine is detected in stability testing, often years after the formulation was finalised.
How Nitrosamine Formation Happens in a Formulation
Three conditions need to be present together for a nitrosamine to form: a nitrosating agent, an amine and an environment that allows the reaction to proceed. Remove any one of these and the risk drops sharply.
The nitrosating agent. Nitrite is the most common source. It can be present as a trace impurity in excipients such as diluents, fillers and certain coating polymers, usually originating from the raw materials or water used in their manufacture rather than from the finished excipient's intended chemistry.
The amine. This can come from the API itself, particularly APIs with secondary or tertiary amine groups, or from amine containing excipients and additives used elsewhere in the formulation.
The environment. Acidic conditions accelerate nitrosation. So does elevated temperature and extended storage time. A formulation stored at room temperature for two years has more opportunity for a slow reaction to proceed than one with a shorter shelf life, which is why nitrosamine risk assessments must account for the full labelled shelf life and not just initial release testing.
A formulator who understands which of these three elements is present in their formulation can target the assessment instead of testing everything against everything. If the API has no amine functionality and no amine containing excipients are used, the nitrite content of individual excipients becomes far less critical. If the API does carry an amine group, nitrite contributing excipients deserve close attention regardless of how small the contribution looks on paper.
What a Risk Assessment Actually Requires
The FDA's three step framework gives structure to what would otherwise be an open ended exercise. The first step is a paper based risk assessment covering the API synthesis route, the excipients in the formulation and the packaging materials. The second step is confirmatory testing where risk is identified, generally following established analytical methods such as USP General Chapter 1469. The third step is implementing process or formulation changes where testing confirms a risk above acceptable limits.
Acceptable intake limits are expressed in nanograms per day and vary by nitrosamine. NDMA and NMBA carry an acceptable intake limit of 96 nanograms per day, while NDEA, NMPA, NIPEA and NDIPA carry a limit of 26.5 nanograms per day. These limits are converted into a parts per million specification based on the drug product's maximum daily dose, which means the same excipient nitrite level can represent a different level of risk depending on the dosage form it ends up in.
For nitrosamine drug substance related impurities, which are structurally similar to the API itself, the FDA has introduced a Carcinogenic Potency Categorization Approach that assigns compounds into five potency categories with acceptable intake limits ranging from 26.5 to 1500 nanograms per day. This matters for formulators working with APIs that have complex amine structures, where a generic excipient nitrite specification is not sufficient on its own.
What Suppliers Should Provide
This is the section that determines whether a formulator can complete a risk assessment without chasing information from multiple sources.
Nitrite content data on the excipient itself. A documented nitrite level, ideally with batch to batch consistency data over time rather than a single historical measurement. Diluents used in larger proportions in a formulation typically show nitrite levels around 1 microgram per gram with low variability, and a supplier who can demonstrate this consistency removes one variable from the formulator's assessment entirely.
A written position on nitrosamine risk for the excipient. This does not need to be a full risk assessment of the customer's formulation, which is not the supplier's responsibility. It needs to state clearly what the excipient contributes, under what conditions, and what data supports that statement.
Manufacturing process information relevant to nitrosamine formation. Where in the process nitrite could be introduced, and what controls are in place to limit it. This is not a request for proprietary process detail. It is a request for the formulator to understand whether the nitrite level they see today is representative of what they will see across future batches.
Change notification commitments. If a raw material source, a process step or a specification changes in a way that could affect nitrite content, the formulator needs to know before the change happens, not after a stability failure prompts an investigation.
Certifications that support the documentation. EXCiPACT GMP certification and US DMF registration are not nitrosamine specific certifications, but they establish the quality system context within which nitrite data is generated and maintained. A supplier operating under these frameworks has the traceability infrastructure to answer follow up questions, which matters when an assessment needs to be revisited after a regulatory update.
This is the standard a formulator should expect from any pharma raw material supplier in India working in regulated markets. Whether the requirement is for a tablet coating materials supplier or a broader pharmaceutical ingredients supplier across the formulation, the documentation expectation does not change. Excipient supplier qualification for a regulated market formulation should treat this nitrite and risk documentation as a standard part of the technical package, not an exception requested only when a query arises.
Applications by Dosage Form
Common Challenges
Treating excipient nitrite as a fixed specification rather than a range. Nitrite levels can vary between batches even within a supplier's stated specification. A formulator who builds a risk assessment around a single historical value rather than a range may find the assessment no longer holds when a new batch arrives.
Assuming a low individual contribution means no formulation level risk. Multiple excipients each contributing a small amount of nitrite can combine to a level that matters, particularly in formulations with several diluents, binders and coating materials.
Incomplete documentation chains during supplier qualification. When nitrite data exists but is not readily available in a format that supports a regulatory submission, the formulator ends up requesting it reactively, often under time pressure during an audit or a query response.
Reassessing only at the time of a regulatory update. Nitrosamine guidance has changed multiple times since 2020. A risk assessment completed against an earlier version of the guidance may not address newer categories such as nitrosamine drug substance related impurities, and formulations approved before these categories existed may need a fresh look.
Formulation Insights
The relationship between excipient selection and nitrosamine risk is not a reason to avoid any particular excipient category. It is a reason to ask for the right data at the right point in the selection process. A tablet coating polymer manufacturer that documents nitrite consistency and provides a clear process narrative gives a formulation team a head start on their risk assessment that cannot be recovered later if the same questions are raised only after the formulation is locked.
Where a formulation includes an API with known amine functionality, the nitrite contribution from the coating system deserves the same attention as the nitrite contribution from the core tablet excipients. Coating represents the outermost layer of the dosage form and the layer in closest contact with the storage environment over the product's shelf life.
FAQ
1. Does every excipient need a nitrosamine risk assessment?
Every excipient should be considered as part of the formulation level assessment, but the depth of assessment depends on whether the API carries amine functionality and whether the excipient is a known nitrite contributor. Diluents used in large proportions and any amine containing excipients warrant the closest attention.
2. Can a low nitrite level in an excipient still cause a problem?
Yes, if multiple excipients in the formulation each contribute a small amount of nitrite and the API carries an amine group, the combined effect over the shelf life can exceed acceptable limits even when no single excipient looks concerning on its own.
3. How often should nitrite data be requested from a supplier?
At initial qualification and again whenever a regulatory update introduces new impurity categories or revised acceptable intake limits. A supplier with stable, documented batch to batch consistency reduces the need for frequent re-testing.
4. Is EXCiPACT GMP certification a nitrosamine specific certification?
No. It certifies the quality management system under which the excipient is produced, which supports the traceability and documentation needed to respond to nitrosamine related queries, but it does not itself certify nitrite levels.
5. What is the difference between a nitrosamine and a nitrosamine drug substance related impurity?
A nitrosamine drug substance related impurity, or NDSRI, is structurally similar to the API itself rather than being one of the well characterised nitrosamines like NDMA or NDEA. NDSRIs are assessed using the Carcinogenic Potency Categorization Approach, which assigns acceptable intake limits based on structural similarity to known carcinogens.
Conclusion
The formulations most exposed to nitrosamine risk are not the ones with the most complex chemistry. They are the ones where the risk assessment was completed once, against an earlier set of expectations, and never revisited as guidance expanded to cover new impurity categories and new sources. An excipient supplier who can provide nitrite data, batch consistency evidence and a documented manufacturing narrative turns a formulation level risk assessment from a research exercise into a documentation review.
We are India's first EXCiPACT GMP certified polymer excipient manufacturer, and as a pharmaceutical excipient manufacturer in India we are registered under the US DMF and operate under WHO cGMP compliance across the full range. Our quality documentation is structured to support the nitrite level and process information that a nitrosamine risk assessment requires.
Facing Nitrosamine Risk in Your Formulation? Talk to Us.
Tell us which excipients are in your formulation and what stage your risk assessment has reached. We will share the nitrite data and documentation relevant to our products and help you understand where they fit in your assessment.
Write to us at contact@vikramthermo.com
.jpg)
.jpg)
- Venue:
- Date:
- Booth:
- Time:
- Hosted by:
- Venue:
- Date:
- Booth:
- Time:
- Hosted by:
